Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Academic Article


Published In

  • Circulation  Journal
  • Digital Object Identifier (doi)

    Author List

  • Virani SS; Akeroyd JM; Nambi V; Heidenreich PA; Morris PB; Nasir K; Michos ED; Bittner VA; Petersen LA; Ballantyne CM
  • Start Page

  • 2572
  • End Page

  • 2574
  • Volume

  • 135
  • Issue

  • 25